These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16480436)

  • 1. Assessment of the economic value of the INTERCEPT blood system in Belgium.
    Moeremans K; Warie H; Annemans L
    Transfus Med; 2006 Feb; 16(1):17-30. PubMed ID: 16480436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
    Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U
    Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.
    Bell CE; Botteman MF; Gao X; Weissfeld JL; Postma MJ; Pashos CL; Triulzi D; Staginnus U
    Clin Ther; 2003 Sep; 25(9):2464-86. PubMed ID: 14604745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellners Y
    Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands.
    Janssen MP; van der Poel CL; Buskens E; Bonneux L; Bonsel GJ; van Hout BA
    Transfusion; 2006 Jun; 46(6):956-65. PubMed ID: 16734812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of pathogen inactivation technology for platelet concentrates in Japan.
    Staginnus U; Corash L
    Int J Hematol; 2004 Nov; 80(4):317-24. PubMed ID: 15615255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of a European strain of West Nile virus in single- donor platelet concentrate using the INTERCEPT blood system.
    Gallian P; Vignoli C; Dombey AM; Mayaudon V; Lin L; Galichet V; Cantaloube JF; De Micco P
    Vox Sang; 2006 Nov; 91(4):345-7. PubMed ID: 17105611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
    Konnopka A; Conrad K; Baerwald C; König HH
    Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes.
    Vitale MG; Roye BD; Ruchelsman DE; Roye DP
    Spine J; 2007; 7(3):292-300. PubMed ID: 17482112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion-transmitted infectious diseases.
    Allain JP; Stramer SL; Carneiro-Proietti AB; Martins ML; Lopes da Silva SN; Ribeiro M; Proietti FA; Reesink HW
    Biologicals; 2009 Apr; 37(2):71-7. PubMed ID: 19231236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
    Kim SY; Billah K; Lieu TA; Weinstein MC
    Am J Prev Med; 2006 Jun; 30(6):498-506. PubMed ID: 16704944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.